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Antiviral activityFoot-and-mouth disease (FMD) is one of the most serious threats to the livestock industry. Despite the
availability of a vaccine, recent outbreaks in disease-free countries have demonstrated that development of
novel FMD control strategies is imperative. Here we report the identiﬁcation and characterization of bovine
(bo) interferon lambda 3 (IFN-λ3), a member of the type III IFN family. Expression of boIFN-λ3 using a
replication-defective human adenovirus type 5 vector (Ad5-boIFN-λ3) yielded a glycosylated secreted
protein with antiviral activity against FMD virus (FMDV) and vesicular stomatitis virus in bovine cell culture.
Inoculation of cattle with Ad5-boIFN-λ3 induced systemic antiviral activity and up-regulation of IFN
stimulated gene expression in multiple tissues susceptible to FMDV infection. Our results demonstrate that
the type III IFN family is conserved in bovines and boIFN-λ3 has potential for further development as a
biotherapeutic candidate to inhibit FMDV or other viruses in cattle.e los Santos).
Inc.Published by Elsevier Inc.Introduction
Foot-and-mouth disease virus (FMDV) is the etiologic agent of one
of the most devastating diseases that can affect cloven-hoofed
livestock. Infection with FMDV causes an acute disease that spreads
very rapidly and is characterized by fever, lameness and vesicular
lesions on the feet, tongue, snout and teats, with high morbidity but
lowmortality (Grubman and Baxt, 2004). With the exception of North
America, Western Europe, New Zealand and Australia, FMD is
enzootic in the rest of the world and disease control is achieved by
inhibition of animal movement, slaughter of infected and in contact
animals, disinfection of contaminated premises and vaccination with
an inactivated whole virus antigen. However, use of this vaccine is not
recommended in FMD free-countries due to technical limitations in
differentiating vaccinated from infected animals, the need of
expensive high containment facilities to produce the antigen and
the more severe trade restrictions established by the international
organization of animal health for animals or animal products derived
from countries that use this vaccine (OIE, 2007). Furthermore, since
the current vaccine does not confer protection until at least ﬁve to
seven days post-vaccination, vaccinated animals are susceptible to
FMD prior to this time. Thus, in recent years the OIE has recognized
that to be successful, FMD control programs should include the use ofantivirals and/or immunomodulatory molecules that, in addition to
newly developed marker vaccines would rapidly control the disease
before the onset of the vaccine-induced adaptive immune response
(Scudamore and Harris, 2002).
In all vertebrates, expression of interferons (IFN) constitute the
ﬁrst step in the immune response against viral infection and, indeed,
administration of IFNs as biotherapeutics has been effective in
controlling several viral infections (Basler and García-Sastre, 2002;
Stark et al., 1998; Fensterl and Sen, 2009). In the case of FMDV, we
have previously demonstrated that treatment of bovine, porcine and
ovine cells with type I or type II IFNs dramatically inhibits viral
replication (Chinsangaram et al., 1999, 2001; Moraes et al., 2007).
Furthermore, swine inoculated with a replication-defective human
adenovirus 5 vector (Ad5) that delivers porcine (po) IFN-α were
sterilely protected when challenged with FMDV 24 h and up to 3–
5 days post-inoculation (Chinsangaram et al., 2003; Dias et al., 2011;
Moraes et al., 2003). Studies to understand the mechanism by which
type I and II IFNs protect swine against FMD have shown that at least
some IFN stimulated genes (ISGs) and migration of immune cells to
the sites of FMDV infection play a signiﬁcant role in controlling viral
replication (Chinsangaram et al., 1999; de los Santos et al., 2006; Diaz-
San Segundo et al., 2010; Moraes et al., 2007). However, a similar
approach in cattle has only shown delayed disease and reduced
clinical signs (Wu et al., 2003).
Recently, a new family of IFNs has been described, type III IFN or
IFN-λ (Kotenko et al., 2003; Sheppard et al., 2003). These IFNs are
related to the type I IFN gene family and also to the interleukin (IL) 10
284 F. Díaz-San Segundo et al. / Virology 413 (2011) 283–292family of ligands. Within the type III IFN family, three structurally
related members have been identiﬁed in humans, mice and chickens:
IFN-λ1 (IL29), IFN-λ2 (IL28A) and IFN-λ3 (IL28B) (Karpala et al.,
2008; Kotenko et al., 2003; Sheppard et al., 2003) and two members,
IFN-λ1 (IL29) and IFN-λ3 (IL28B) have been recently identiﬁed in
swine (Sang et al., 2010a, 2010b). Similar to type I IFN, expression of
type III IFN is induced in response to recognition of pathogen
associatedmolecular patterns (PAMPs) and activation of transcription
factors, such as nuclear factor κB (NF-κB) and interferon regulatory
factors (IRF)-3 and -7 (Iversen et al., 2010). Type III IFN signals
through a heterodimeric cellular receptor that is composed of IL28-
Rα, a type III IFN speciﬁc subunit, and IL10-Rβ, a subunit shared by
other IL10 related cytokines. Despite the fact that type I and type III
IFNs act on different receptors, they trigger strikingly similar
responses through the activation of multiple members of the signal
transducer and activator of transcription (STAT) family (Zhou et al.,
2007). However, expression of the type III IFN receptor in a tissue
speciﬁc manner, mainly in epithelia, has been proposed as one of the
mechanisms evolved by different organisms to possibly prevent and
protect themselves from viral invasion through the skin and mucosal
surfaces (Sommereyns et al., 2008) especially with pathogens like
FMDV, whose ﬁrst site of replication is the mucosa (Arzt et al., 2010).
Although not strictly robust, IFN-λ has been shown to induce
protection against several viruses in cell culture, as well as in animal
models, including herpes simplex virus type 2 (HSV-2) (Ank et al.,
2006), hepatitis B and hepatitis C viruses (Marcello et al., 2006; Robek
et al., 2005), inﬂuenza virus and other human pneumotropic viruses
(Mordstein et al., 2010). IFN-λ has also been described as an inducer
of antiproliferative activity by triggering host antitumor mechanisms
(Maher et al., 2008). Furthermore, a role in the adaptive immune
response, as well as modulation of the balance of Th1/Th2 immune
responses has been recently proposed for IFN-λ1 biasing toward a
stronger block of Th2 responses (Jordan et al., 2007; Morrow et al.,
2010).
So far, no member of the type III IFN family has been described in
bovines and sequencing of the bovine genome has not provided
evidence of predictive sequences for this type of IFN (The Bovine
Genome Sequencing and analysis consortium et al., 2009). Very
recently a predictive sequence of an IL28B-like mRNA has been
deposited in GenBank but no related literature is available.
Here we report the identiﬁcation, cloning and characterization of a
member of the bovine (bo) type III IFN family, boIFN-λ3 or boIL28B.
Nucleotide and protein sequence analyses indicated that the cloned
boIFN-λ3 displays signiﬁcant homology with respect to previously
identiﬁed porcine, human and mouse IFN-λ3 sequences, and to the
predicted dog, chicken, rat and monkey sequences. Using an Ad5
vector we have expressed boIFN-λ3 protein in tissue culture and
tested for biological antiviral activity against FMDV and vesicular
stomatitis virus (VSV). Consistently, ISG expression was up-regulated
in bovine cells after treatment with boIFN-λ3. Furthermore, inocula-
tion of cattle with Ad5-boIFN-λ3 resulted in systemic antiviral activity
and induction of ISG mRNA and protein expression in several tissues,
including those of the upper respiratory tract and skin.
These results indicate that bovine type III IFN behaves similarly to
other species orthologs and has the potential of being developed as a
biotherapeutic to limit FMDV infection, replication and/or spreading.
Results
Identiﬁcation of boIFN-λ3
In previous studies we used DNA microarrays to evaluate
transcription proﬁles of bovine cells infected with FMDV (Zhu et al.,
2010). Although bovine type III IFNs sequences had not been
identiﬁed when we initiated this project, we included in the
microarray several probes with sequence homology to human typeIII IFNs. Interestingly, we observed that upon FMDV infection there
was signiﬁcant up-regulation of the mRNA detected by the human
IFN-λ3 probes. Therefore to better understand if type III IFN plays any
role in controlling FMDV infection, we ampliﬁed the full length coding
sequence of boIFN-λ3 by RT-PCR of mRNA extracted from primary
embryonic bovine kidney (EBK) cells. Analyses of 3 independent
clones allowed us to identify a fragment of 585 nucleotides within an
818 nucleotide region, corresponding to a full length open reading
frame of 195 amino acids that displayed signiﬁcant sequence
homology to the previously identiﬁed IFN-λ3 (IL28B) sequences in
Sus scrofa (po) (NM_001166490), Homo sapiens (hu) (NM_172139)
Mus musculus (mu) (NM_177396) and an IFN-λ3 predicted Bos taurus
(bo) sequence recently deposited in GenBank (XM_002695050)
(Fig. 1). The closest homology was observed with respect to the
S. scrofa counterpart with values of 85% for the DNA and 76% for the
protein sequences. Comparison of protein sequences across species
and localization of the putative signal sequence, suggested that a
previously deposited boIFN-λ3 sequence (predictive) likely contains
an aberrant N-terminal extension. To this end the identiﬁed boIFN-λ3
sequence encodes for a protein of MW=21587.6 with a pI of 8.20, a
predicted signal peptide between amino acids 1 and 23 (Bendtsen
et al., 2004) and a putative N-linked glycosylation sequence between
amino acids 112 and 115 (NetNGlyc 1.0 Server, Gupta et al., 2004)
(Fig. 1B).
boIFN-λ3 displays antiviral activity in vitro
Expression of boIFN-λ3
To corroborate the predicted biochemical properties and deter-
mine if the identiﬁed boIFN-λ3 sequence encoded for a biologically
active IFN product, we expressed the protein using a replication-
defective human Ad5 vector containing the cytomegalovirus (CMV)
immediate early promoter to drive transcription of the gene (Moraes
et al., 2001). Porcine IBRS2 cells, which do not express endogenous
type I IFNs (Chinsangaram et al., 2001), were infected with the Ad5-
boIFN-λ3 vector and recombinant protein expression was analyzed in
cell extracts and supernatants. A proteinwithmultiple bands between
21 and 34 kDa was detected by western blot analysis in both fractions
using a speciﬁc rabbit polyclonal antibody produced in our laboratory
(Fig. 2A). Infection of IBRS2 cells with a control Ad5 vector did not
result in the induction of a comparable protein. Addition of
tunicamycin, an inhibitor of N-linked glycosylation, to the Ad5-
boIFN-λ3 infected IBRS2 cells, resulted in a protein with a discrete
MW of approximately 21 kDa in both, the cell extract and the
supernatant, indicating that boIFN-λ3 protein was glycosylated at Asn
residues.
Detection of antiviral activity in vitro
The biological activity of the expressed boIFN-λ3 protein was
tested in EBK and Madin–Darby bovine kidney (MDBK) cells which
were pretreated for 24 h with ﬁltered supernatants from Ad5-boIFN-
λ3 infected IBRS2 cells and challenged with FMDV and VSV
respectively. Fig. 2B shows that the supernatants from Ad5-boIFN-
λ3 infected IBRS2 cells contained between 32,000 and 64,000 U/ml of
antiviral activity against FMDV. A stronger response 51,200 to 102,400
U/ml was observed when the same supernatant was tested in MDBK
cells challengedwith VSV (Fig. 2C). The speciﬁcity of the responsewas
determined by incubating the same supernatants with rabbit anti
boIFN-λ3 serum prior to the assay. Most of the antiviral activity, 80 to
90%, was neutralized by addition of the speciﬁc polyclonal antibody
(Fig. 2D). No background antiviral activity was detected in super-
natants from uninfected or control Ad5-Blue infected porcine IBRS2
cells and no neutralization of antiviral activity was observed by
addition of preimmune rabbit serum (Fig. 2D, arrow), or anti-bovine
IFN-α antibody (Fig. 2D, arrowhead). These results indicated that the
Fig. 1. DNA and amino acid sequence analysis of boIFN-λ3 (boIL28B). Nucleotide (A) and deduced amino acid (B) sequences were aligned to known homologous sequences. pred.:
predicted; hu: human; mu: murine; po: porcine; aa: amino acid; cds: coding sequence. Predicted signal peptide: amino acids 1–23 (boxed in red). Putative N-glycosylation site:
amino acids 112–115 (boxed in blue).
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Fig. 2. Characterization of boIFN-λ3 biochemical activity. IBRS2 cells were infected with Ad5-boIFN-λ3 or Ad5-Blue for 24 h in the presence (+) or absence (−) of tunicamycin. Cell
lysates and supernatants were evaluated for the presence of recombinant boIFN-λ3 protein by western blot analysis using a polyclonal rabbit antibody. Pre: Cell lysate of Ad5-boIFN-
λ3 infected cells probed with rabbit pre-immune serum. *: Glycosylated species of boIFN-λ3. U: Un-glycosylated form (A). Antiviral activity of the recombinant boIFN-λ3 protein
expressed in IBRS2 cells was evaluated in primary EBK cells challenged with FMDV (B) and in MDBK cells challenged with VSV (C). Neutralization of antiviral activity with anti-
boIFN-λ3 polyclonal antibody in MDBK cells challenged with VSV. Arrow and arrowhead represent neutralization in the presence of rabbit pre-immune serum and polyclonal anti-
bovine IFN-α, respectively. Asterisk (*) denotes neutralized antiviral activity (D).
286 F. Díaz-San Segundo et al. / Virology 413 (2011) 283–292expressed boIFN-λ3 displays antiviral activity in bovine epithelial
cells.
It has been reported that although type I and type III IFN bind
distinct receptors, they induce similar cellular responses (Kotenko
et al., 2003; Sheppard et al., 2003; Zhou et al., 2007; Dumoutier et al.,Table 1
Bovine oligonucleotide primer and probe sequences for real-time RT-PCR.
Gene Accession # Forward primer Ta
CCL2 EU276059 GCTACTCACAGTAGCTGCCTTCAG-30 CC
CCL3 AY077840 AGCCAGGTCTTCTCGGCAC-124 AT
CCL20 NM_174263 CCAGTATTCTTGTGGGCTTCACA-166 AG
CXCL10 EU276062 GTCATTCCTGCAAGTCAATCCTG-142 CC
GAPDH NM_001034034 GCATCGTGGAGGGACTTATGA-572 CA
IFN-α XM_001250455 AGCACACCTTCCAGCTTTTCA-319 CA
IFN-β M15477 CTACAGCTTGCTTCGATTCCAA-278 AC
IL10-Rβ NM_001076975 TTTGACAAACTGAGCGTCATCA-913 AA
IL28-Rα XM_868941 CCAGCTGCCGCATTGTCT-435 CC
IFN-λ3 HQ317919 ACTCATCCCTGGGCCACA-335 CC
IRF7 BC151518 GGACTGTGACACGCCCATCT-1535 AC
ISG15 BC102318 GCGTGTACAAGCGGACCAGT-409 CT
MDA5 XM_615590 AGGAGTCAAAGCCCACCATCT-2541 AT
MX1 AY251193S10 CGTCCGGAGCACGAAGAA-595 CG
OAS1 AY243505 CCAAAGTTGTGAAGGGTGGC-161 CT
PKR BC126646 TGCCAAACTGGCTTATGAAAAG-545 CA
RIGI XM_580928 GACTCATTGCCCCAGGTCATT-1192 CT2004). We therefore assayed the antiviral activity in MDBK or EBK
cells treated with boIFN-α and boIFN-λ3 or a combination of both
IFNs against VSV and FMDV, respectively. We also incubated the cells
with poIFN-α, which we have demonstrated to exhibit antiviral
activity in bovines (Wu et al., 2003). Overall, treatment with differentqMan probe Reverse primer
GAGGTGCTCGCTCAGCCAG-56 GCGACTTGGGAGTTAATTGCA-98
TTGGCGCTGACACC-144 AGAAGCAGCAGGCCGTTG-178
CAGCTGGCCAATGAAGCCTGTG-190 GGTGTAAAAGACAACTGCATTGATG-239
ACGTGTCGAGATTA-166 CCCATTCTTTTTCATTGTGGC-204
CTGTCCACGCCATCACTGCCA-594 GGGCCATCCACAGTCTTCTG-638
GAGGGCTCGGCC-341 GGAGGCTCTTGTCCCACACA-376
GTCAGAGCCTTAAA-302 CTGCCC AGAG TT TGAC-341
GTGTCTGAAAGCTGCAA-938 CGGCCCCAGGGTTCA-973
CCAACCAGATATG-454 TCCTTCCAGAAATTCACCTCATAGT-494
TGGAGCAGCCCCTTCTCACG-354 GCTTGGAGTGGATGTTCTGCA-397
TTCGGCACCTTCT-1558 CCCGGAACTCCAGCAGTTC-1596
GGCTGTCTTTTGAAGGGAGGCCC-430 AGCGGGTGCTCATCATCC-474
TGGCGCTGGACACA-2563 TTCTGTGTCATGGGCTTGAACT-2606
TCCGGAGCACGAAGAA-614 CGTCCGGAGCACGAAGAA-650
CAGGCAAAGGC-183 TGATCGTCCCCTGAGGGTC-216
GAAACAATGAGAGATGG-574 TCACCACACGCAGCACTGA-613
GACTGCCTCAGTTGGCGTTGGA-1216 TCGGCTGTGTTTTTGGCAT-1259
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antiviral activity, as expected and previously reported for other
species (Supp. Fig. 1).Analysis of gene expression in bovine cells treated with boIFN-λ3
To better understand the mechanism of antiviral activity elicited
by boIFN-λ3 in bovine cells, we measured the levels of RNA by
quantitative real time reverse transcription PCR (qRT-PCR) of IFNs and
several ISGs whose expression has been shown to be up-regulated by
type III IFN in other species (Ank et al., 2006). For the analysis of gene
expression we focused on IFN-α, IFN-β, IFN-λ3 and ISGs, including
chemokines CCL2, CCL3, CCL20, CXCL10, activators of the IFN pathway
such as IRF-7, RIG I and MDA5 and some genes with known antiviral
activity, ISG15, Mx1, OAS1 and PKR (Table 1). We also measured the
expression of type III IFN receptors, IL28-Rα and IL10-Rβ. Little or no
induction of type I or type III IFN mRNA was observed in these cells
after treatment with boIFN-λ3, boIFN-α or poIFN-α. However, a dose
response effect was observed for several ISGs when the cells were
incubated with each IFN independently (Fig. 3) and 50 U of each IFN
were sufﬁcient to reach the saturation level. We did not detect any
enhanced effect when boIFN-λ3 was used in combination with either
poIFN-α or boIFN-α. Analysis of the expression of the type III IFN
receptors (IL28B-Rα and IL10-Rβ) showed considerable basal levels of
RNA with ct values of 24–28 as compared to ct values of 20–21 for the
housekeeping gene GAPDH, in samples containing 5 ng of total RNA.
Expression of such levels of IL28B-Rα and IL10-Rβ is consistent with
the sensitivity of EBK cells to type III IFN.Fig. 3. Examination of gene expression in bovine cells treated with IFNs. EBK cells were trea
combination, as indicated. RNA was isolated and gene expression was analyzed by qRT-PC
induction of cells treated with IFN with respect to cells treated with medium (mock). Shaded
gene induction according to each treatment.Ad5-boIFN-λ3 induces antiviral activity and ISG up-regulation in cattle
In order to test the response of cattle to inoculation of Ad5-boIFN-
λ3, a pilot experiment was performed with 4 animals that were
inoculated with Ad5 vectors expressing IFNs as transgenes or empty
vector control Ad5-Blue (Moraes et al., 2001). We chose a dose of 1011
pfu of Ad5-IFN/animal based on previous studies with type I IFN, in
which 1010 pfu/animal was required to induce any measurable
antiviral activity in serum, and treatment with Ad5-poIFN-α was
evaluated at the same time because this vector displayed the highest
antiviral activity despite the species difference (Wu et al., 2003). The
systemic IFN biological antiviral activity one day after administration
of the vectors was 25 U/ml for the animal inoculated with Ad5-Blue,
50 U/ml for the animals receiving each IFN alone and 160 U/ml for the
animal receiving the combination of IFNs, indicating that all Ad5 IFN
constructs were expressing the recombinant proteins.
Expression of ISGs in tissues
Twenty-four hours after Ad5 inoculation, animals were eutha-
nized, necropsies were performed and tissues of the respiratory tract,
skin and lymphoid organswere sampled based on previously reported
studies about the pathogenesis of FMDV (Arzt et al., 2010). Peripheral
bloodmononuclear cells (PBMCs)were also extracted before and after
treatment. The expression of several genes including IFN and ISGs was
measured by qRT-PCR and an induction of 2 fold or more was
considered as a “hit” and was represented in red. While treatment
with either Ad5-IFN had 95 and 98 hits respectively, treatment with
the combination of Ad5-IFNs displayed 139 hits in comparison to the
Ad5-Blue control animal (Fig. 4). Approximately 48% of these hitsted for 24 h with varying concentrations of boIFN-λ3, poIFN-α or boIFN-α alone or in
R. Primers and probes are described in Table 1. Results are expressed as relative fold
colored areas represent induction relative to mock treated cells. Color coding indicates
Fig. 5. Expression of type III IFN receptors, IL28-Rα and IL10-Rβ, in bovine tissues. Gene
expression was analyzed by qRT-PCR in RNA samples extracted from the bovine tissue
of the control animal (larynx [LAR], proximal lung [LUN], dorsal soft palate [DSP],
trachea [TRA], coronary band skin [COR], tongue [TOG], nasopharynx [NSP], retro-
pharyngeal lymph node [RLN], palatine tonsil [TON], spleen [SPL], interdigital skin [INT]
and oropharynx [ORP]) and normalized against GAPDH.
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addition of each independent effect or higher) suggesting that
combination treatment results in a stronger IFN response. The
expression of IRF-7 was highly up-regulated by the combination
treatment in all examined tissues. It was also noticeable that in
PBMCs, Ad5-poIFN-α induced twice the number of up-regulated
genes as compared to Ad5-boIFN-λ3. In parallel, the levels of mRNA
for type III IFN receptor subunits were also measured to evaluate the
sensitivity of each analyzed tissue to this type of IFN. Constitutive
basal expression of type III IFN receptors (IL28-Rα and IL10-Rβ) was
detected in all analyzed tissues indicating that these tissues could be
susceptible to type III IFN (Fig. 5). Interestingly, expression of both
receptor subunits, and particularly IL28-Rα, was up-regulated after
IFN treatment in most of the analyzed tissues including the naso- and
oropharynx (Fig. 4), tissues recently reported as the initial site of virus
replication after aerosolization of FMDV (Arzt et al., 2010).
Detection of Mx1 protein
Visualization of Mx1 protein by immunohistochemistry (IHC) is a
common technique to evaluate in situ, the effects of type I and type III
IFNs (Jung and Chae, 2006; Sommereyns et al., 2008). One day after
inoculation, animals treatedwith Ad5-boIFN-λ3 showed increasedMx1
protein signal in the epithelium of the dorsal soft palate, other mucosal
epithelia of the upper airways and different locations of skin including
coronary band or interdigital skin as compared to Ad5-Blue inoculated
animals (Fig. 6A, compare panels c and gwith a and e and Table 2).With
the exception of the proximal lung, the Mx1 signal in epithelial tissues
was always weaker in the animal treated with Ad5-poIFN-α than in the
animal treatedwith Ad5-boIFN-λ3 (Fig. 6A, panels b and f, and Table 2).
In contrast, the animal treated with the combination of Ad5-IFNs
showed the highest Mx1 signal in most of the tissues (Fig. 6A, panels d
and h and Table 2). No or almost undetectable positive signal was seen
in the control animal (Fig. 6A, panels a and e). The levels of Mx1 proteinFig. 4. Examination of gene expression in tissues and PBMCs isolated from bovines treated
measured by qRT-PCR in RNA samples extracted from the listed bovine tissues (dorsal soft pa
lung [LUN], tongue [TOG], retropharyngeal lymph node [RLN], palatine tonsil [TON], spleen
expressed as relative fold induction values of Ad5-IFN treated with respect to Ad5-Blue-c
[brightest red (greater than 1000 fold) to black (lower than 2 fold)]. E denotes enhanced udetected by IHC correlated with the up-regulation in the expression of
mRNA analyzed by qRT-PCR (Fig. 6B and Table 2). Interestingly, the
protein signal in lymphoid tissue, i.e., palatine tonsil, retropharyngeal
lymph node or spleen in the animal inoculated with Ad5-poIFN-α was
stronger than the signal observed in the same organs of the animal
treated with Ad5-boIFN-λ3 (Table 2).
Taken together, our results indicated that boIFN-λ3 has antiviral
activity in cattle in vivo and induces the expression of several ISGs
when used alone or in combination with IFN-α.
Discussion
Members of the type III IFN family, also known as IL28A, IL28B and
IL29, have been recently identiﬁed in several species includingwith Ad5-boIFN-λ3, Ad5-poIFN-α, or a combination of both IFNs. Gene expression was
late [DSP], nasopharynx [NSP], oropharynx [ORP], larynx [LAR], trachea [TRA], proximal
[SPL], interdigital skin [INT], coronary band skin [COR] and PBMCs [PBM]). Results are
ontrol treated animals. Relative gene induction is represented by red color indexing
p-regulation with the combination treatment.
Fig. 6. Detection of Mx1 expression by immunohistochemistry (IHC) and real time RT-PCR. A. Tissues from oropharynx (panels a to d) and from coronary band skin (panels e to h)
were harvested from bovine necropsies 24 hpi with Ad5-Blue (control), Ad5-poIFN-α, Ad5-boIFN-λ3 or a combination of Ad5-boIFN-λ3 and Ad5-poIFN-α (combination). Mx1
protein was detected by staining withmouse mAb against humanMx1, and a biotinylated anti mouse/avidin–peroxidase complex developed with Fast Red TR/Naphthol. Positivity is
shown in bright purple. Sections were counterstained with Harry's hematoxylin (blue). Magniﬁcation, ×10. Insert in panel d shows a higher magniﬁcation (×60) of the oropharynx
basal epithelium layer in the indicated region. B. Relative expression of Mx1mRNA analyzed by real time RT-PCR in oropharynx and skin from coronary band. Primers and probes are
described in Table 1. Results are expressed as relative fold induction of mRNA in tissue from cows treated with Ad5-IFNs with respect to mRNA in tissue from a cow treated with Ad5-
Blue (control). Relative mRNA levels were determined by comparative cycle threshold analysis and a relative fold induction of 2 or less was considered as background which is
depicted as a light gray area across the graphs. Expression of GAPDH mRNA was used as normalizer.
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2010b; Sheppard et al., 2003). These IFNs are expressed in response to
virus infections and mediate the induction of antiviral activity (Ank
et al., 2006; Kotenko et al., 2003; Meager et al., 2005; Robek et al.,
2005). However, no sequences for type III IFN are available in theTable 2
Expression of Mx1 in different tissues in animals treated with Ad5-poIFNα, Ad5-boIFNλ
or the combination of the two.
Ad5-poIFNα Ad5-boIFNλ3 Combination
Dorsal soft palate +a/2.9b ++/2.1 +++/6.9
Oropharynx ±/5.7 ++/9.7 +++/12.4
Nasopharynx +/20.5 ++/15.0 +++/28.6
Proximal lung ++/2.3 ±/1.0 +++/4.2
Tongue ±/3.1 ++/13.4 +++/11.2
Retro LN ++/2.3 +/1.1 ++/1.7
Palatine tonsil +++/2.4 +/1.7 +++/4.9
Spleen ++/3.9 ±/0.7 ++/5.9
Skin interdigital ±/15.9 +/7.2 ++/11.9
Skin coronary band ±/2.4 +/4.7 ++/9.6
a Semi-quantitative analysis ofMx1 protein signal in tissue sections detected by IHC:−
is negative and +++maximum signal (±b+b++b+++).
b Level of fold induction of mRNA detected in each tissue by real time RT-PCR,
compared with the same tissue in a non-treated animal. Only animals with an
expression ≥2 are considered up-regulated.published bovine genome (The Bovine Genome Sequencing and
Analysis Consortium et al., 2009). By using PCR primers homologous
to human sequences, we ampliﬁed the mRNA coding for one member
of the bovine type III IFN family, boIFN-λ3 (boIL28B). Although the
same sequence was obtained in several independent clones, the
presence of allelic polymorphism, a common feature within IFN
families, cannot be ruled out (van Pesch et al., 2004; Sang et al., 2010a,
2010b). More studies are required to demonstrate this hypothesis.
Cloning of the identiﬁed boIFN-λ3 gene and expression inmammalian
cells resulted in the synthesis of an N-linked glycosylated protein of
approximately 21–34 kDa that displayed speciﬁc antiviral activity
against FMDV and VSV as examined by plaque or virus titer reduction
assays in bovine tissue cultures. Analysis of gene expression in cells
treated with boIFN-λ3 showed patterns similar to those displayed by
treatment with bovine or porcine IFN-α. Induced genes included PKR
and OAS1, which have antiviral activity against FMDV (Chinsangaram
et al., 1999; de los Santos et al., 2006), and CXCL10 which has been
proposed to play a role in immune cell inﬁltration to the sites of FMDV
replication (Diaz-San Segundo et al., 2010). Expression of ISG15
was also signiﬁcantly up-regulated in bovine cells treated with IFNs.
Recently we have shown that in bovine cells infected with FMDV
there is an up-regulation of ISG15 (Zhu et al., 2010). Interestingly, the
levels of ISG15 are higher when the infection is carried out with an
attenuated strain of FMDV, leaderless virus, as compared to wild-type
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has a role in controlling FMD.
To determine if boIFN-λ3 had activity in vivo, we performed an
initial experiment inoculating one cow each with Ad5 vectors
delivering poIFN-α, boIFN-λ3, a combination of both, or an empty
control (Ad5-Blue). We chose poIFN-α instead of boIFN-α because in
previous experiments we had observed a good antiviral response of
this IFN despite the species difference (Wu et al., 2003). We
inoculated the animals with a relatively high dose of Ad5-vector
(1011 pfu/animal) to have a measurable response without FMDV
challenge. Despite these high Ad5 doses, the levels of antiviral activity
in serum were rather low, however signiﬁcant variation had been
previously observed in cattle and swine inoculated with type I IFN
alone (Wu et al., 2003; Dias et al., 2011) and protection against FMD
has still been observed (Dias et al., 2011). Inoculation of cattle with
Ad5-boIFN-λ3 alone or in combination with Ad5-poIFN-α induced a
systemic antiviral activity and up-regulation of speciﬁc gene expres-
sion in multiple tissues, particularly in the upper respiratory tract, the
initial site of virus infection, and in the skin, the main site of FMDV
replication (Arzt et al., 2010). FMDV is highly sensitive to the actions
of type I and type II IFNs in vitro and in vivo (Chinsangaram et al., 1999,
2001; Dias et al., 2011; Moraes et al., 2007), however, since treatment
with IFN-α only conferred partial protection in cattle (Wu et al.,
2003), there is an active interest in developing and testing new
antivirals with proven efﬁcacy in this species.
Similar to the results in vitro, expression of several genes was
induced in the tissues and PBMCs of cows treated with type III IFN.
Although most of the analyzed genes were also induced by IFN-α,
there is evidence in other species suggesting that selective expression
of the type III IFN receptor in epithelial cells contributes to a better
response to this type of IFN and prevents undesired side effects (Ank
et al., 2006; Sommereyns et al., 2008). In support of this hypothesis,
Ank et al. (2006) have shown that type III IFN treatment is effective in
controlling herpes simplex virus 2 infection in epithelial tissue in
vaginal mucosa. It has been reported that upon aerosolization of
FMDV there is a pre-viremic phase when the virus mainly targets
epithelial cells of the upper respiratory tract; once viremia is
established, the virus preferentially infects epithelial cells of the
skin and mouth (Arzt et al., 2010; Pacheco et al., 2010). Therefore,
targeting antivirals to epithelial cells of the upper respiratory tract
could potentially help control FMDV ampliﬁcation at the initial site of
infection. Indeed, expression of type III IFN receptors, IL28-Rα and
IL10-Rβ was detected in most of the bovine tissues analyzed, but up-
regulation, especially for IL28-Rα, was highest in the oro-, nasophar-
ynx, tongue and palatine tonsil, all tissues present in the upper
airways. The strongest and broadest up-regulation in gene expression
in response to IFN treatment was observed for IRF-7, with highly
enhanced up-regulation for the combination treatment of type I and
type III IFNs, particularly in the oro-, nasopharynx and palatine tonsil.
Expression of IRF-7 is induced by IFNs and mediates a positive
feedback loop that controls the expression of most subtypes of IFN-α
and other immunomodulatory molecules (Honda et al., 2005; Marie
et al., 1998). Although we did measure, by qRT-PCR, the levels of
boIFN-α we did not detect its induction with any treatment (data not
shown). However, since there are at least 13 predicted IFN-α gene
sequences within the bovine genome (The Bovine Genome Sequencing
and Analysis Consortium et al., 2009) it is possible that other subtypes
were induced but not detectedwith the available reagents. Interestingly,
in PBMCs, the number of up-regulated genes induced by Ad5-poIFN-α
was almost double as compared to Ad5-boIFN-λ3 treatment, indicating
that blood cells are not so susceptible to type III IFN. In support of this
observation, Lasfar et al. have reported that bone marrow-derived
macrophages and splenocytes showed a very weak activation in
response to type III IFN treatment (Lasfar et al., 2006). Overall, up-
regulation of gene expression indicated a systemic response to type I and
type III IFN treatment.Our results suggest that, as previously reported in other species,
boIFN-λ3 is involved in establishing an antiviral state in speciﬁc
bovine tissues such as those present in the upper airways and the skin
which are the preferred sites for FMDV replication. Therefore, use of
boIFNλ3 has potential for development as an antiviral strategy to
control FMD or other bovine diseases that target similar organs.
Material and methods
Cell lines and viruses
Human 293 cells (ATCC CRL-1573) were used to generate and
propagate recombinant adenovirus. EBK cells were obtained from the
Animal Plant and Health Inspection Service (APHIS), Ames, Iowa and
porcine kidney cells (IBRS2) were obtained from the Foreign Animal
Disease Diagnostic Laboratory (FADDL) at the Plum Island Animal
Disease Center (PIADC), Greenport, NY. EBK cells were used for
determination of IFN bioactivity against FMDV and IBRS2 cells were
used to express IFN proteins from Ad5-IFN constructs. MDBK cells
(ATCC CCL-22) were purchased from the American Type Culture
Collection (ATCC, Rockville, MD) and used for determination of IFN
bioactivity against VSV. All cells were maintained in Eagle's minimal
essential medium (EMEM, GIBCO BRL, Invitrogen, Carlsbad, CA)
containing either 10% calf serum or 10% fetal bovine serum (FBS)
supplemented with antibiotics. Baby hamster kidney cells (BHK-21,
ATCC CCL-10) were used to propagate and titer FMDV. These cells
were maintained in EMEM containing 10% calf serum and 10%
tryptose phosphate broth supplemented with antibiotics. FMDV
subtype A12 was generated from the full-length infectious clone
pRMC35 (Rieder et al., 1993) and used for the biologic assay of IFN.
VSV serotype New Jersey (VSVNJ) was provided by FADDL at PIADC.
Recombinant Ad5 viruses including Ad5-boIFN-λ3, Ad5-poIFN-α and
Ad5-Blue were obtained as previously described (Moraes et al., 2003).
Identiﬁcation, cloning and expression of boIFN-λ3
RNA was isolated from EBK cells infected, at a multiplicity of
infection (MOI) of 1 for 6 h, with an attenuated FMDV serotype A12
lacking the leader protein coding region (leaderless virus), and using
an RNeasy mini kit (Qiagen, Valencia, CA) following the manufac-
turer's directions. Approximately 1 μg of RNA was treated with DNase
I (Sigma, St. Louis, MO) andwas used to synthesize cDNAwithM-MLV
reverse transcriptase (Invitrogen) and random hexamers following
the manufacturer's directions. Two oligonucleotides: 5′ ATCGA-
TATGGCCCCGGGCT GCACGCT 3′ (FW) and 5′ TCTAGATTAGACA-
CACTGGTCTCCGCTGGC 3′ (RW) containing ClaI and XbaI restriction
sites, respectively, were designed to amplify cDNA containing the
putative IFN-λ3 (IL28B) sequence using bovine cDNA as template and
PfuUltra™ high-ﬁdelity DNA polymerase (Agilent Technologies, Santa
Clara, CA). The ampliﬁed PCR fragment was cloned in pPCR4 blunt
TOPO (Invitrogen) and the sequence of 3 independent clones was
determined by standard DNA sequencing in an ABI 3730 XL system
(Applied Biosystems, Foster City, CA). The sequence of boIFN-λ3 was
identical in all 3 clones and it was submitted to GenBank, and assigned
accession number HQ317919. One of the clones was digested with
ClaI/XbaI and the resulting 588 bp boIFN-λ3 DNA fragment was
ligated to ClaI/XbaI digested pAd5-Blue (Moraes et al., 2001) for
expression in mammalian systems. Recombinant Ad5 viruses,
including Ad5-boIFN-λ3, Ad5-poIFN-α and Ad5-Blue, were produced
by transfection of 293 cells with previously PacI-digested pAd5
plasmids. Viruses were plaque-isolated, propagated in 293 cells and
puriﬁed by CsCl gradient centrifugation. Viral titer was determined by
the method of tissue culture infectious dose 50 (TCID50) and
converted to plaque-forming units (pfu)/ml. To analyze the protein
expressed by Ad5-boIFN-λ3, IBRS2 cells were infected with the Ad5-
boIFN-λ3 vector and cellular extracts and supernatants were collected
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blot analysis. A polyclonal antibody was obtained by inoculation of
rabbits with the same Ad5-boIFN-λ3 vector. When indicated
tunicamycin (10 μg/ml) was added during the infection to examine
for the presence of N-linked glycosylation.
Determination of IFN biological activity
Plaque reduction assay
IBRS2 cells were infected with the Ad5 vectors and 24 hpi the
supernatants were removed, centrifuged to pellet cell debris, and
ﬁltered through a Centricon 100 at 4000 rpm for 10 min to remove
Ad5 vector. EBK and MDBK cells were pre-treated with 2-fold serial
dilutions of the ﬁltered supernatants. When required, a neutralizing
polyclonal antibody was used (1 μl rabbit immune serum per ml of
cell supernatant). Twenty-four hours later, supernatants were
removed, and cells were washed and challenged with approximately
100 pfu of FMDV (EBK cells) or VSV (MDBK cells) for 1 h followed by
overlay with gum tragacanth and incubation for 24–48 h. Plaques
were visualized by staining with crystal violet. Antiviral activity was
determined as the reciprocal of the highest supernatant dilution that
resulted in a 50% reduction in the number of plaques relative to the
number of plaques in the untreated cells. Results were expressed as
units of antiviral activity/ml of sample. A similar technique was used
to measure antiviral activity in plasma derived from inoculated cattle.
Virus yield reduction assay
EBK cells were treated as previously described with 2-fold serial
dilutions of ﬁltered IBRS2 supernatants infected with Ad5-IFNs.
Twenty-four hours later, treated cells were washed with PBS followed
by infection with FMDV at a MOI of 1. One hour after the infection,
cells were washed with 2-(N-morpholino) ethanesulfonic acid buffer
(MES) pH=6 followed by incubation in cell culture media for an
additional 7 h (total incubation period is 8 h). Supernatants were then
collected and virus yield was measured on BHK-21 cells by standard
plaque assay (Chinsangaram et al., 1999). Results were expressed as
log10/ml of sample.
Animal experiment
An animal experiment was performed under the approval of the
InstitutionalAnimal Care andUseCommittee (IACUC)of thePlumIsland
Animal Disease Center and animals were kept under strict controlled
conditions in the PIADC biosafety level 3 animal facilities. Four male
Holstein cows, of about 400 lb each, were inoculated intramuscularly
(IM) with 2×1011 pfu of Ad5 vectors encoding different IFNs or Ad5-
Blue control. One animal was inoculated with 2×1011 pfu of Ad5-Blue
(control), one animalwith 1011pfu of Ad5-poIFN-α and1011 pfuofAd5-
Blue, one animal with 1011 pfu of Ad5-boIFN-λ3 and 1011 pfu of Ad5-
Blue and one animal was inoculated with a combination of 1011 pfu of
Ad5-poIFN-α and 1011 pfu of Ad5-boIFN-λ3. Twenty-four hours after
Ad5 inoculation, animals were euthanized and necropsies were
performed to isolate multiple tissues and analyze the expression of
several genes by qRT-PCR. Animals were bled before and after the
treatment formeasurement of IFN biological antiviral activity in plasma,
as described above and PBMCs were extracted from heparinized blood
to obtain mRNA.
Analysis of mRNA
A qRT-PCR assay was standardized and used to evaluate the mRNA
levels of multiple genes in monolayers of EBK cells or bovine tissues
and PBMCs exposed to different IFNs and control Ad5-Blue vector.
RNA and cDNAwere prepared as described above. An aliquot (1/40) of
the cDNA was used as template for qRT-PCR using TaqMan Universal
PCR Master Mix (Applied Biosystems). Primers and TaqMan minorgroove binding (MGB) probes were designed with Primer Express™
software v.1.5 (Applied Biosystems). Forward and reverse primers
were purchased from Invitrogen and the FAM-labeled TaqMan MGB
probes from Applied Biosystems. Bovine glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as internal control to normalize
the values for each sample. The sequences for the primers and probes
are listed in Table 1. Reactions were performed in an ABI Prism 7900
Sequence detection system (Applied Biosystems).
IHC for detection of Mx1 protein in bovine tissues
Frozen 4 μm-sections of multiple bovine tissues obtained after
necropsy were mounted onto electrostatically charged glass slides
(SuperFrost Plus, Fisher Scientiﬁc, Worcester, MA) and ﬁxed for 10 min
in acetone at−20 °C. Thereafter, the slideswere kept at−70 °C for up to
8 wk, until they were stained. For immunostaining, the slides were
incubated with the primary antibody mouse mAb anti-human Mx1,
kindly provided by Dr. Otto Haller, University of Freiburg. The bound
primary antibodies was detected by the avidin–biotin–peroxidase
complex technique (Vectastain ABC Kit Elite; Vector, Burlingame, CA)
according to the manufacturer's instructions and developed with Fast
Red TR/naphthol (Sigma, St. Louis,MO). Slideswere counterstainedwith
Harry's hematoxylin and coverslipped by using routine methods. To
control the speciﬁcity of antibody binding, a duplicate negative control
serial section treated with nonspeciﬁc primary antibody was used.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.02.023.
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